share_log

Stifel Maintains Buy on Tandem Diabetes Care, Raises Price Target to $40

Moomoo 24/7 ·  Apr 23 13:01

Stifel analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $37 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment